Clinical Trial Update: HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial investigating hydroxychloroquine (HCQ) effects on PAR-4 levels in patients with resectable solid tumors; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Peng Wang, MD PhD | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2019-07-23